Wyeth Europa: European Commission Approval Makes Enbrel(R) First and Only Biologic Treatment Approved for Severe Psorias

Wyeth is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. It is also a global leader in vaccines, biotechnology and animal health care.

    
    REFERENCES
    1. Enbrel EMEA SPC.
       http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-P...
    2. Christophers E. Psoriasis - Epidemiology and Clinical Spectrum. Clin
       Exp Dermatol 2001;26:314-320
    3. National Psoriasis Foundation. Plaque Psoriasis.
       http://www.psoriasis.org/about/psoriasis... Accessed October
       2008
    4. National Psoriasis Foundation. Medical facts about psoriasis in
       childhood. http://www.psoriasis.org/about/youth/par...
       Accessed October 2008
    5. National Psoriasis Foundation. Emotional effects of psoriasis on
       children. http://www.psoriasis.org/about/youth/par...
       Accessed October 2008
    6. Paller, AS et al. Etanercept treatment for children and adolescents
       with plaque psoriasis. N Engl J Med 2008;358:241-51

For further information, please contact: Wyeth: Gill Markham, Communications - Europe, Middle East and Africa, Direct Tel: +44-1628-692536, Email: markhagl@wyeth.com; Danielle Halstrom, Communications - Global, Direct Tel: +1-484-865-2020, Email: halstrd@wyeth.com; OgilvyHealthPR: Mary Barrington-Ward, Tel: +44-207-108-6066, Email: mary.barrington-ward@ohpr.com